1.
Brigitte Mohr, Uta Oelschlaegel, Christian Thiede, Michelle Meredyth Stewart, Gerhard Ehninger, Uwe Platzbecker. The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells. haematol [Internet]. 2009Feb.27 [cited 2024Dec.21];94(3):430-1. Available from: https://haematologica.org/article/view/5198